Cell>Point News & Publications
Diagnostic Imaging
Posted on: March 24th, 2020
CENTENNIAL, Colorado, March 24, 2020 – Cell>Point announced today its plans to move forward with its research program to clinically develop 99mTc-EC-Amifostine and 177Lu-EC-Amifostine to assess, treat and follow-up with confirmatory imaging for people who contract COVID-19. For example, EC-Amifostine is metabolized by alkaline phosphatase (ALP) to a thiol analog, followed by scavenging free-radicals and…
Read More
Posted on: January 21st, 2020
CENTENNIAL, Colorado, January 21, 2020 – Cell>Point announced today, based on its sponsored chelator and therapeutic research conducted at the University of Texas M.D. Anderson Cancer Center on Platinum-Oncardia and 177Lu-Oncardia, and the positive results of its lung cancer imaging trials with 99mTc-Oncardia®, that it will be moving forward with these two intra-nuclear therapeutics expanding…
Read More
Posted on: January 21st, 2020
CENTENNIAL, Colorado, May 17, 2019 – Cell>Point announced today that it plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in patients suffering from coronary artery disease using the company’s new one-vial Oncardia® (ethylenedicysteine-glucosamine) kits. The 60 patient trial study is being conducted in the U.S. Today, slightly greater than 6 million…
Read More
Posted on: September 19th, 2018
CENTENNIAL, Colorado, September 18, 2018 – CellPoint announced today that it has entered into an automated production agreement with KP Pharmaceutical Technology, Inc. to produce 1mg vials of its lead agent Oncardia®(ethylenedicysteine-glucosamine). CellPoint is currently completing Phase 2b and 3 nuclear imaging trials with 99mTc-Oncardia® in both cardiology and oncology imaging. The new formulation will simplify the…
Read More
Posted on: March 19th, 2018
Published March 19, 2018, Hindawi Contrast Media & Molecular Imaging https://cellpointweb.com/wp-content/uploads/2019/11/Noninferiority-of-99mTc-Ethylenedicystein.pdf
Read More
Posted on: October 3rd, 2016
Oncotarget, Advance Publications 2016 https://cellpointweb.com/wp-content/uploads/2019/11/12413-186535-1-PB-2016-EC-G-Paper.pdf
Read More
Posted on: August 25th, 2016
CENTENNIAL, Colo., August 24, 2016 – Cell>Point today announced it has entered into license agreements with Vyripharm Biopharmaceuticals for the use of its In-Situ Hydrogel, N4 Technology and Oligosaccharide (Dual Agent) Technology to develop applications in combination with cannabinoids for nuclear imaging and therapeutic applications for neurologic disorders including, but not limited to, posttraumatic stress disorder (“PTSD”),…
Read More
Posted on: June 17th, 2016
CENTENNIAL, Colo., June 16, 2016 – Cell>Point today announced that it has entered into an exclusive license agreement for China, Hong Kong and Macau with United Eastern Pharmaceutical (UEP), a company representing a consortium from the U.S. and China. The license agreement covers Cell>Point’s diagnostic radiopharmaceutical Oncardia® (ethylenedicysteine-glucosamine) which was developed for labeling with technetium-99m for…
Read More
Posted on: February 26th, 2015
CENTENNIAL, Colo., January 15, 2015 – Cell>Point announced today positive results following conclusion of a Head and Neck Cancer imaging trial for 99mTc-Oncardia® conducted pursuant to a physician initiated IND study at the University of Chicago Medical Center. The study imaged patients with squamous cell carcinoma of the head and neck (SCCHN) with technetium-99m- labeled Oncardia®…
Read More
Posted on: September 21st, 2014
Published: September 2014, Bio Medical Research International https://cellpointweb.com/wp-content/uploads/2019/11/Patched-Targeting-Peptides-for-Imaging-and-Treatment-of-Hedgehog-Postive-Breast-Tumors.pdf
Read More
